Liberate Medical, an innovator in the world of transformative respiratory care, has achieved success with the recent closure of its $6.2 million Series B financing round. Co-led by a large strategic investor and Scientific Health Development, this transformational investment adds strength to Liberate Medical’s Board and sets it on a course for success. This is a milestone moment that is furthering the development of novel non-invasive neurostimulation devices, set to revolutionize the world of respiratory care.
Liberate Medical is proud to announce that it has secured the Series B funding for VentFree – the world’s first non-invasive, breath-synchronized, neuromuscular electrical stimulator created to combat at-risk patients facing difficulty in weaning off mechanical ventilation. With this vital funding, VentFree aims to reduce the duration of invasive mechanical ventilation treatments while lowering the risks of prolonged mechanical ventilation, including hospital-acquired infections, quality of life deterioration, and even death.
Notably, the stimulator has been awarded Breakthrough Device Designation by the FDA, has FDA Emergency Use Authorization, and CE marking in the European Union. Building upon two successful pilot randomized controlled trials previously conducted in Europe and Australia, the Series B funding will enable VentFree to complete the upcoming PREVENT trial for full commercial launch.
“We are thrilled to have Scientific Health Development and our strategic partner join us as co-leads in this Series B financing round,” said Angus McLachlan, CEO of Liberate Medical. “Their support and expertise will be instrumental as we conduct the PREVENT trial and prepare for full commercialization of VentFree.”
“SHD is proud to support Angus and the Liberate Medical team,” said Andrew Offer, General Partner and CEO of Scientific Health Development. “I am honored to join the board of directors and play a role in changing the standard of care for weaning mechanically ventilated patients. VentFree will improve quality of life for patients and their families.”
About Liberate Medical
Liberate Medical is a medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders.
About Scientific Health Development
Scientific Health Development (SHD) is a Dallas-based venture capital firm focused on early-stage investments in high-impact medical device and diagnostics companies across a variety of specialties. Formed in 2006, SHD is motivated to improve patient outcomes and healthcare economics.